– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation–
– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022–
Read more at globenewswire.com